MY
MYGN.US Myriad Genetics Inc
- Market cap
- USD 543M
- P/E
- -
- P/B
- 2.01x
- ROE
- -60.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MYGN.US undervalued?
Graham numberThe Graham number of Myriad Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Myriad Genetics Inc fundamental analysis
No fundamental analysis for Myriad Genetics Inc yet.
Myriad Genetics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected delet…
Full company profileMyriad Genetics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Myriad Genetics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 741M | 729M | 744M | 851M | 557M | 691M | 678M | 753M | 838M | 825M | 792M |
| Gross Profit | 583M | 558M | 567M | 650M | 379M | 493M | 476M | 517M | 585M | 577M | 536M |
| Operating Income | 153M | 44.0M | 122M | 7.60M | -195M | -191M | -124M | -145M | -88.0M | -67.8M | -146M |
| EBITDA | 183M | 90.5M | 178M | 85.0M | -123M | 12.3M | -84.7M | -197M | -59.5M | -331M | -111M |
| Net Income | 117M | 17.4M | 133M | 4.60M | -224M | -27.2M | -112M | -263M | -127M | -366M | -162M |
| EPS | 1.60 | 0.25 | 1.85 | 0.06 | -2.99 | -0.35 | -1.39 | -3.18 | -1.41 | -3.92 | -1.69 |
| Balance Sheet | |||||||||||
| Total Assets | 881M | 1.21B | 1.18B | 1.56B | 1.42B | 1.32B | 1.20B | 1.15B | 1.03B | 707M | 609M |
| Total Liabilities | 132M | 441M | 209M | 474M | 538M | 353M | 313M | 363M | 327M | 339M | 340M |
| Shareholders' Equity | 748M | 768M | 966M | 1.09B | 881M | 968M | 886M | 783M | 701M | 368M | 269M |
| Cash & Short-term Investments | 159M | 151M | 181M | 137M | 151M | 339M | 115M | 141M | 102M | 150M | 107M |
| Total Debt | - | 99.1M | 9.30M | 234M | 289M | 92.3M | 145M | 152M | 140M | 210M | 209M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 166M | 106M | 116M | 83.7M | 83.7M | 18.6M | -106M | -111M | -8.70M | 1.80M | -40.7M |
| Capital Expenditure | 5.00M | 6.10M | 8.40M | 8.60M | 8.60M | 18.0M | 45.3M | 73.3M | 29.7M | 27.4M | 12.4M |
| Free Cash Flow | 161M | 100M | 108M | 75.1M | 75.1M | 600K | -152M | -184M | -38.4M | -25.6M | -53.1M |
| Ratios | |||||||||||
| ROE | 15.7% | 2.3% | 13.8% | 0.4% | -25.4% | -2.8% | -12.6% | -33.6% | -18.2% | -99.4% | -60.1% |
| ROA | 13.3% | 1.4% | 11.3% | 0.3% | -15.8% | -2.1% | -9.3% | -23.0% | -12.4% | -51.8% | -26.5% |
| Net Profit Margin | 15.8% | 2.4% | 17.9% | 0.5% | -40.2% | -3.9% | -16.5% | -35.0% | -15.2% | -44.4% | -20.4% |
| Debt to Equity | - | 0.13x | 0.01x | 0.21x | 0.33x | 0.10x | 0.16x | 0.19x | 0.20x | 0.57x | 0.78x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Myriad Genetics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 340M | 4.55 | - |
| 2019 | USD 340M | 4.47 | 7,391.3% |
| 2018 | - | - | - |
| 2017 | USD 403M | 5.86 | 2,316.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Mar 26, 2009.
Who owns Myriad Genetics Inc
- Insiders 4.28%
- Institutions 95.72%
- Public & others 0.00%
- Shares outstanding 95.9M
- Free float 79.6M
Top funds holding MYGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.04M | 3.17% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.88M | 3.00% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.30M | 2.40% | 0.00% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.36M | 1.42% | -24.07% | Sep 2026 |
| Canada Life US Small-Mid Cap Growth F | 1.29M | 1.34% | +69.87% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 1.25M | 1.30% | +1.62% | Sep 2026 |
| Columbia Small Cap Value Discv A | 1.14M | 1.18% | 0.00% | Sep 2026 |
| Vanguard Strategic Equity Inv | 1.02M | 1.07% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 859K | 0.90% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 714K | 0.74% | +0.27% | Oct 2026 |
| Fidelity Small Cap Index | 702K | 0.73% | -30.51% | Aug 2026 |
| iShares Biotechnology ETF | 689K | 0.72% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 538K | 0.56% | +1.07% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 530K | 0.55% | -15.83% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 507K | 0.53% | +0.23% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 488K | 0.51% | -16.97% | Sep 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 471K | 0.49% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 455K | 0.47% | -5.34% | Sep 2026 |
| Schwab Small-Cap Equity | 371K | 0.39% | -6.34% | Sep 2026 |
| Goldman Sachs Small Cp Val Insghts Instl | 330K | 0.34% | +9.34% | Jul 2026 |
Top institutions holding MYGN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.9M | 11.35% | +22.51% | Jun 2026 |
| Millennium Management LLC | 6.62M | 6.90% | -0.73% | Jun 2026 |
| Vestal Point Capital LP | 5.74M | 5.98% | +248.00% | Jun 2026 |
| State Street Corp | 4.99M | 5.20% | +12.68% | Jun 2026 |
| D. E. Shaw & Co LP | 4.58M | 4.78% | +1.83% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.08M | 4.25% | +4.00% | Jun 2026 |
| Acadian Asset Management LLC | 3.46M | 3.61% | +10.59% | Sep 2026 |
| Vanguard Portfolio Management, LLC | 3.08M | 3.21% | +19.26% | Jun 2026 |
| AQR Capital Management LLC | 2.77M | 2.88% | +44.68% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.48M | 2.59% | -21.70% | Jun 2026 |
| Geode Capital Management, LLC | 2.42M | 2.52% | +4.17% | Jun 2026 |
| Assenagon Asset Management SA | 2.06M | 2.15% | +42.57% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.06M | 2.14% | -13.07% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.89M | 1.97% | -9.43% | Jun 2026 |
| Charles Schwab Investment Management Inc | 1.74M | 1.81% | -3.37% | Jun 2026 |
| Qube Research & Technologies | 1.67M | 1.74% | -1.46% | Jun 2026 |
| Federated Hermes Inc | 1.57M | 1.64% | -20.54% | Jun 2026 |
| Two Sigma Investments LLC | 1.56M | 1.62% | +21.31% | Jun 2026 |
| Nuveen, LLC | 1.55M | 1.61% | +68.18% | Jun 2026 |
| Mackenzie Investments | 1.54M | 1.60% | 0.00% | Jun 2026 |
Myriad Genetics Inc company profile
- Company name
- Myriad Genetics Inc
- Ticker
- MYGN.US
- Exchange
- USA Stocks
- Listed since
- Oct 5, 1995
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,700
- Fiscal year end
- December
- Address
- 322 North 2200 West, Salt Lake City, UT, United States, 84116
- Phone
- 801 584 3600
- Website
- myriad.com
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics Inc management
10- Mr. Samraat S. RahaPresident, CEO & Director · born 1973
- Mr. Benjamin R. WheelerCFO & Principal Accounting Officer · born 1984
- Mr. Mark S. VerrattiChief Operating Officer · born 1968
- Dr. Dale Muzzey Ph.D.Chief Scientific Officer · born 1980
- Mr. Paul J. Diaz J.D.Consultant · born 1962
- Mr. Raj JampaChief Technology Officer
- Mr. Matthew ScaloSenior Vice President of Investor Relations
- Ms. Jennifer L. Fox J.D.Chief Legal Officer · born 1973
- Dr. Patrick M. Burke Ph.D.Executive Vice President of Corporate & Business Development
- Ms. Shereen SolaimanChief People Officer · born 1973